...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on medical diagnostics. >fTwo novel biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma.
【24h】

fTwo novel biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma.

机译：f用于诊断卵巢癌的两种新型生物标记物间皮素和HE4。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

INTRODUCTION: There is a need to improve the diagnosis and prognosis of ovarian carcinoma, particularly the serous type of cancer. Mesothelin and HE4 are two novel biomarkers which are expressed in serous ovarian carcinoma and can be measured in serum and other body fluids, including urine, by using ELISA. The measurement of antibodies to these markers can provide additional useful information. AREAS COVERED: A literature search was performed to as recent as December 1 2010, using the Internet (e.g. PubMed) on articles concerning mesothelin and HE4 for the diagnosis of ovarian carcinoma. The authors also included up to date recent information from the research performed in their own laboratory. EXPERT OPINION: The combination of CA125 with HE4 facilitates the triaging of women with a pelvic mass and detects more stage I/II tumors than CA125, the present 'gold standard', when used alone. Assaying urine for HE4 or mesothelin may detect early ovarian carcinoma more often than assaying serum. Antibodies to mesothelin and HE4 are more frequent in women with ovarian carcinoma or with certain types of infertility than in controls. No presently available biomarker or multi-marker panel lends itself to screening large populations of symptomless women to make possible detection of high grade serous ovarian carcinoma at stage I or II. The authors anticipate, within the next 5 years, that a greater emphasis will be given to the fact that the different subtypes of ovarian carcinoma represent different types of disease. Each different type of disease will require a different diagnostic approach and more efforts will focus on high grade serous ovarian carcinoma for which the clinical need is the greatest.
机译：引言：有必要改善卵巢癌，尤其是浆液性癌症的诊断和预后。间皮素和HE4是两种新的生物标志物，它们在浆液性卵巢癌中表达，可以通过ELISA在血清和其他体液（包括尿液）中进行测量。对这些标志物的抗体的测量可以提供其他有用的信息。覆盖的地区：直到2010年12月1日，使用Internet（例如PubMed）对有关间皮素和HE4的文章进行卵巢癌诊断的文献检索。作者还包括了在他们自己的实验室中进行的研究的最新信息。专家意见：与单独使用时，CA125（目前的“黄金标准”）相比，CA125与HE4的结合可促进女性盆腔肿块的分流，并能检测出更多的I / II期肿瘤。检测尿液中的HE4或间皮素可能比检测血清更频繁地检测出早期卵巢癌。与对照组相比，卵巢癌或某些类型的不育妇女中间皮素和HE4的抗体更为常见。目前没有可用的生物标志物或多标志物检测小组可用于筛查大量无症状女性，从而可能在I或II期检测出高度浆液性卵巢癌。作者预计在未来5年内，将更加重视以下事实：不同类型的卵巢癌代表不同类型的疾病。每种不同类型的疾病都需要不同的诊断方法，而更多的工作将集中在临床需求最大的高级浆液性卵巢癌上。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号